China’s biotech firm Singleron bags around $100m in Series B round

Chin’s Singleron Biotechnologies has raised nearly $100 million in its Series B round, it said in a statement on Tuesday. 

The oversubscribed Series B round was led by Lake Bleu Capital, a healthcare industry-focused investment firm with offices in Hong Kong and Shanghai. 

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter